SymBio Pharmaceuticals Limited

Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause)

Disclosure of the monthly exercise status of stock acquisition rights issued via third-party allocation. Includes a detailed table defining exercised shares, exercise amount, issued shares, and other items constituting the exercise status. Monitoring future exercise trends and dilution impact is...

【SymBio Pharmaceutical】Exercise of Stock Acquisition Rights in Large Volume｜July 2026

As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights, bringing the total issued shares to approximately 76,434,210.

Notice Regarding the Completion of Early Redemption of the First Unsecured Unsubordinated Bonds

Notice on Monthly Exercise Status of the 58th Stock Acquisition Rights and the 66th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through Third-Party Allotment

Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy

Under a CRADA led by NIH/NINDS, the first patient enrollment for an IV BCV clinical trial targeting PML has been completed. The trial is conducted at the NIH Clinical Center in Bethesda, Maryland. No impact on the Full Year 2026...